BioAge Labs (NASDAQ:BIOA) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of BioAge Labs (NASDAQ:BIOA) from a sell rating to a hold rating in a research report sent to investors on Saturday morning.

Several other research firms have also issued reports on BIOA. Oppenheimer assumed coverage on shares of BioAge Labs in a research report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Friday, April 24th. Morgan Stanley set a $23.00 price target on shares of BioAge Labs in a research report on Wednesday, February 4th. Piper Sandler assumed coverage on shares of BioAge Labs in a research report on Tuesday, January 27th. They set an “overweight” rating on the stock. Finally, Needham & Company LLC assumed coverage on shares of BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $46.25.

BioAge Labs Trading Up 1.0%

Shares of BIOA opened at $17.99 on Friday. BioAge Labs has a 12 month low of $3.67 and a 12 month high of $24.00. The firm’s 50 day moving average is $18.55 and its 200-day moving average is $15.38. The stock has a market capitalization of $798.40 million, a PE ratio of -7.50 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA) last announced its earnings results on Friday, May 8th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.19. BioAge Labs had a negative net margin of 896.11% and a negative return on equity of 27.86%. The company had revenue of $2.77 million for the quarter. Equities research analysts predict that BioAge Labs will post -2.7 earnings per share for the current fiscal year.

Institutional Trading of BioAge Labs

A number of hedge funds have recently added to or reduced their stakes in the stock. CWM LLC boosted its position in BioAge Labs by 39.9% in the fourth quarter. CWM LLC now owns 3,693 shares of the company’s stock valued at $49,000 after buying an additional 1,053 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in BioAge Labs by 24.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock valued at $196,000 after buying an additional 2,917 shares in the last quarter. Barclays PLC boosted its position in BioAge Labs by 9.3% in the fourth quarter. Barclays PLC now owns 37,780 shares of the company’s stock valued at $500,000 after buying an additional 3,222 shares in the last quarter. Bank of America Corp DE boosted its position in BioAge Labs by 46.3% in the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock valued at $65,000 after buying an additional 3,517 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in BioAge Labs in the third quarter valued at approximately $27,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.